Related by context. All words. (Click for frequent words.) 65 hemoglobin A1c HbA1c 64 #μg [001] 61 â ‰ ¥ 61 urine albumin 61 mEq L 60 nmol l 60 ug kg 60 serum IGF 60 x ULN 60 per deciliter mg 60 mmHg systolic 60 HbA1C 60 HbA 1c levels 60 pmol L 59 #.#mmol L [002] 59 % Confidence Interval 59 mm Hg systolic 59 mU L 59 HbA 1c 59 pmol liter 59 mmol l 59 SGPT 59 pg mL 59 μg dl 59 glycated hemoglobin 59 EDSS score 59 mm Hg diastolic 59 μmol l 59 aspartate aminotransferase AST 59 Hb A1C 58 microg 58 mmol L. 58 plasma cortisol 58 ng dL 58 IU ml 58 mU liter 58 μg kg 58 glycated hemoglobin HbA1c 58 alanine aminotransferase 58 Ann Intern Med 58 NOAEL 58 QIDS SR 58 Montgomery Åsberg Depression 58 colesevelam HCl 58 #mg/day [002] 58 mmHg diastolic 57 μg L 57 A1c levels 57 urinary sodium excretion 57 Hb A1c 57 Hemoglobin A1c 57 mean baseline HbA1c 57 fasting triglyceride levels 57 baseline HbA1c 57 mg BID dose 57 MADRS score 57 μg d 57 -#.# mg dL [002] 57 glycosylated hemoglobin HbA1c 57 LDL triglycerides 57 receiving Vectibix monotherapy 57 onset diabetes mellitus 57 glycated hemoglobin levels 57 mL sec 57 fasting plasma glucose FPG 57 HOMA IR 57 mIU ml 57 Fasting plasma glucose 57 Eur J Endocrinol 57 oral antidiabetic medication 57 blood Phe 57 corticosteroid dose 57 fasting plasma glucose 56 serum sodium 56 ≥ 56 adjunctive placebo 56 Nephrol Dial Transplant 56 mg TID 56 aspartate aminotransferase 56 PSA nadir 56 hemoglobin A1c levels 56 sUA 56 Fasting blood glucose 56 Kidney Int 56 alanine aminotransferase ALT 56 #.#mg/dL 56 iPTH 56 ìg 56 mg qd 56 mCi m 2 56 NYHA functional class 56 achieved ACR# 56 HbA1c levels 56 Scale EDSS score 56 #mg/dL [001] 56 Fasting glucose 56 hydroxyvitamin D levels 56 glycosylated hemoglobin 56 NNT = 56 fluticasone salmeterol 56 mg/m2/day 56 serum cortisol 56 QTcF 56 8 OHdG 56 μg mL 56 apolipoprotein B 56 atorvastatin #mg 56 #mg/dL [002] 56 mL/min/#.# m 2 56 calculated creatinine clearance 56 mEq 56 leukocyte count 56 #mg/day [001] 56 BLLs 56 mmol 56 UPDRS motor 55 albumin excretion 55 hemoglobin A1C 55 μmol L 55 mg QD 55 serum sodium levels 55 % CI #.#-#.# [003] 55 dosing cohort 55 kBq kg 55 blood phenylalanine Phe 55 ADCS CGIC 55 ml min 55 mIU L 55 mL kg 55 pCi l 55 Psoriasis Area 55 estimated glomerular filtration 55 serum phosphate 55 PASI scores 55 lumbar spine BMD 55 postmenopausal osteoporotic women 55 permanently discontinue Vectibix 55 serum potassium 55 fructosamine 55 serum aminotransferase levels 55 CI -#.# 55 DAS# CRP 55 fasting blood glucose 55 hyperphenylalaninemia HPA due 55 #OHD 55 #mmHg [001] 55 neutrophil counts 55 statistical significance p 55 Eur Respir J 55 moderate renal impairment 55 hydroxy vitamin D 55 Unified Parkinson Disease 55 statin monotherapy 55 isoprostane 55 CCyR 55 albumin excretion rate 55 mIU mL 55 μg dL 55 baseline A1C 55 g carbo 55 uM 55 binary restenosis 55 mL/min/#.# m2 55 mg tid 55 serum LDL cholesterol 55 metformin monotherapy 55 kcal d 55 undetectable viral 55 elevated ALT 55 plasma leptin 55 log# copies mL 55 ARCOXIA 54 PREZISTA r arm 54 NIH CPSI 54 #.#mmol l [002] 54 -#.# ± [002] 54 serum uric acid 54 X ULN 54 HbA1C levels 54 REYATAZ r arm 54 mg m² 54 Rating Scale MADRS 54 kg -1 54 ULORIC 54 ABC/3TC 54 ug ml 54 urinary albumin excretion 54 serum lipid levels 54 atazanavir ritonavir 54 morphometric vertebral fractures 54 exhaled NO 54 IFN α 54 serum HBV DNA 54 nmol L 54 oocytes retrieved 54 #OHD levels 54 ml kg 54 CDAI score 54 AUC0 54 IU mL 54 systemic corticosteroid 54 -#.# ± [001] 54 -#.# log# 54 lispro 54 Severity Index PASI 54 8mg/kg 54 #mg/m# [001] 54 glycosylated hemoglobin levels 54 #.#-# b [002] 54 urinary N telopeptide 54 mg calcium 54 serum phosphorus 54 NPH insulin 54 specific antigen PSA 54 HbA1c 54 evaluable subjects 54 serum magnesium 54 primary hypercholesterolemia 54 NovoLog ® Mix 54 fasting triglycerides 54 macroalbuminuria 54 mg simvastatin 54 #mg/dl 54 pg ml 54 #ug [002] 54 creatinine clearance 54 sUA levels 54 lopinavir r arm 54 TAXUS p value 54 mmHg p = 54 hours postdose 54 low dose Iluvien 54 ng dl 54 - -Books Market Segmentation 54 μg liter 54 HBeAg 54 ARB telmisartan 54 mcg dl 54 umol L 54 nmol 54 biochemical relapse 54 min -1 54 hypophosphatemia 54 ACR# response 54 Lupuzor ™ 54 tPSA 53 microgram kg 53 serum folate 53 NATRECOR R 53 SpO 2 53 serum triglyceride 53 aged ≥ 53 mcg kg 53 YMRS 53 certolizumab 53 peak VO2 53 mg kg dose 53 mcg dose 53 serum concentrations 53 #.#/#.# mmHg [001] 53 reduce serum phosphate 53 oral glucose tolerance 53 g trans fats 53 erythrocyte sedimentation rate 53 mcg mL 53 AUA Symptom Score 53 MADRS 53 HBV DNA levels 53 Engerix B 53 elevated triglycerides 53 troponin T 53 fasting glucose 53 Montgomery Asberg Depression 53 serum urate 53 plasma triglycerides 53 plasma renin 53 anemia hemoglobin 53 bioavailable testosterone 53 serum prostate 53 Serum creatinine 53 Health Aff Millwood 53 MBq 53 elevated creatinine 53 glulisine 53 Ann Oncol 53 = #.#-#.# 53 μg g 53 lanthanum carbonate 53 GERD symptom 53 Mg Usa 53 dose colchicine 53 triglyceride TG 53 mg eq 53 hepatic insulin sensitivity 53 CLA supplementation 53 hip BMD 53 achieved PASI 53 achieving PASI 53 cells uL 53 overt nephropathy 53 hepatic enzyme 53 QTc 53 ug dose 53 CRESTOR #mg 53 symptomatic intracranial hemorrhage 53 COZAAR 53 LANTUS R 53 BPRS PSS 53 serum bilirubin 53 Negative Syndrome 53 mg BID 53 BMI ≥ 53 aminotransferases 53 ADAS cog 53 urinary albumin 53 thyroid stimulating hormone 53 kilopascals 53 serum triglycerides 53 atherogenic dyslipidemia 53 mg/m2 dose 53 interquartile range 53 ALT elevation 53 #mmHg [002] 53 HBeAg negative patients 53 nmol L. 53 FreeStyle Navigator 53 achieved mucosal healing 53 #mg BID [001] 53 dose Iluvien 53 specific alkaline phosphatase 53 test OGTT 53 Secondary endpoints include 53 symptomatic GERD 53 μSv 53 Biaxin clarithromycin 53 divalproex sodium 53 ACR Pedi 53 #.#-#.# [011] 53 #mg/m# [002] 53 g dl 53 mmol liter 53 Crohn Disease Activity 53 Scale EDSS 52 biphasic insulin aspart 52 cholesterol LDL C 52 3mg 52 urate lowering therapy 52 plasma HCV RNA 52 hypopneas 52 nmol liter 52 #μg [002] 52 mean baseline A1C 52 μV 52 oral prednisolone 52 salmeterol fluticasone propionate 52 systolic diastolic blood 52 nondiabetic patients 52 plasma urate 52 adenoma recurrence 52 BENICAR HCT 52 CI #.#-#.# [001] 52 ertapenem 52 μg m 52 SUVmax 52 mso footer margin 52 lactate dehydrogenase 52 mean serum phosphorus 52 % CI #.#-#.# [005] 52 eNO 52 mg Proellex 52 χ 52 triiodothyronine 52 creatinine ratio 52 Eur J Pharmacol 52 tipranavir r 52 Score DAS# 52 SCIg 52 Am J Cardiol 52 comparator arm 52 % CI #.#-#.# [001] 52 DLQI 52 IRLS score 52 ADHD RS 52 urinary cortisol 52 hemoglobin Hb 52 mmol kg 52 endoscopic remission 52 serum testosterone 52 serum homocysteine 52 p = .# [002] 52 NYHA 52 insulin detemir 52 hsCRP levels 52 total cholesterol LDL 52 Hemoglobin A1C 52 hypogonadal men 52 oxyhemoglobin 52 HDRS 52 LPV r 52 mg/# h 52 Mg Uk 52 SGOT 52 inhaled budesonide 52 mcg dL 52 fasting insulin 52 salmeterol inhalation powder 52 PREZISTA r 52 cd m 52 dehydroepiandrosterone sulfate 52 LVEF 52 NIHSS 52 mCi 52 salmeterol fluticasone 52 amoxicillin clavulanate 52 mH 52 ^ sup -1 52 interleukin IL -6 52 micrograms mcg 52 weekly CSBMs 52 quetiapine XR 52 N telopeptide 52 HGPIN 52 metformin Glucophage 52 annualized relapse 52 mcg kg min 52 IOP lowering 52 Index CDAI 52 Visual Analogue Scale VAS 52 intact parathyroid hormone 52 transaminases 52 FTE staffing 52 elevated LDL 52 XIENCE V PROMUS Stent 52 #.#g/day 52 Acetate Rectal Suppositories 52 candesartan cilexetil 52 #R #R #R [002] 52 OGTT 52 Suppository Hydrocortisone Acetate Rectal 52 budesonide pMDI 52 liver enzymes ALT 52 Secondary endpoints included 52 recurrent VTE 52 l h 52 clinically meaningful improvement 52 kg m² 52 SBP DBP 52 mcg linaclotide 52 PSQI 52 ‰ ¥ 52 severe exacerbations 52 intramuscular dose 52 PANSS total 52 PRADAXA #mg 52 elevated fasting glucose 52 QD dosing 52 INCOME TAX EFFECTS 52 baseline PASI 51 mg dL 51 Apidra ® 51 REMICADE monotherapy 51 HBeAg seroconversion 51 bronchial hyperresponsiveness 51 #.#mmHg 51 % CI #.#-#.# [004] 51 rosuvastatin #mg 51 tertiles 51 #mg dose [002] 51 AUA BPH Symptom Score 51 serum ferritin 51 metformin sulphonylurea 51 arterial oxygen saturation 51 urinary calcium 51 mg orally 51 mg Androxal 51 postdose 51 PEG IFN 51 State Examination MMSE 51 triglyceride concentrations 51 CNS LS 51 #mg BID [003] 51 % CI #.#-#.# [008] 51 serum urate levels 51 μg dose 51 mcL 51 baseline FEV 51 acromegalic patients 51 eGFR 51 hemoglobin concentrations 51 alanine transaminase 51 ps :# 51 HT 1A 51 ug mL 51 elevated LDL cholesterol 51 #.#/#.# mm Hg [003] 51 -#.# log# copies mL 51 serum triglyceride levels 51 dose clopidogrel 51 CK # plasma concentrations 51 serum HCV RNA 51 dose cohort 51 blood Phe levels 51 #.#mg/kg [002] 51 EQ 5D 51 receiving VICTRELIS 51 glucose insulin 51 BMI percentiles 51 improves glycemic 51 milligrams mg 51 Eur Arch 51 triglyceride concentration 51 concentration Cmax 51 sulphonylurea 51 Index CDAI score 51 triacylglycerol 51 plasma folate 51 dose ritonavir 51 p ≤ 51 glycemic variability 51 incontinence episodes 51 MMSE score 51 Secondary endpoints 51 microalbumin 51 4mg/kg 51 QRS duration 51 CIMZIA TM 51 hemoglobin A1c 51 tumor progression TTP 51 microalbumin test 51 cGy 51 unresectable HCC 51 lispro alone 51 asymptomatic carotid stenosis 51 mU 51 normal ULN 51 % CI #.#-#.# [006] 51 underwent surgical resection 51 Lantus ® 51 CK # plasma 51 postintervention 51 benazepril 51 hydroxyvitamin D 51 Visual acuity 51 cells μL 51 male Sprague Dawley 51 WOMAC pain 51 transaminase 51 acarbose 51 pg g 51 anagrelide 51 CIN2 + 51 serum retinol 51 mg dl 51 sham injections 51 baseline Hb 51 serum transaminases 51 euthyroid 51 MCyR 51 undetectable HBV DNA 51 Ishak fibrosis score 51 malondialdehyde MDA 51 sd = 51 unfractionated heparin UFH 51 PCWP 51 milliliters mL 51 SGRQ 51 3mg/kg 51 mm ³ 51 proBNP 51 Apgar scores 51 LDL cholesterol LDL 51 Y BOCS 51 fosamprenavir 51 μg ml 51 A1C levels 51 fraction LVEF 51 c reactive protein 51 HDL triglycerides 51 timepoints 51 IQR 51 Prostate Specific Antigen PSA 51 OADs 51 highest tertile 51 PROCTOCORT ® Suppository Hydrocortisone 51 elevated serum creatinine 51 postprandial blood glucose 51 PRADAXA 51 milliohm 51 μmol 51 Active Trader DARTs 51 mean ± SEM 51 preintervention 51 serum ALT 51 hemoglobin A1C HbA1C 51 #.#mmol L [001] 51 1c HbA 1c 51 glomerular filtration rate 51 Insulin sensitivity 51 FDG uptake 51 intraclass correlation coefficient 51 severe renal impairment 51 lipid lowering agents 51 density lipoprotein cholesterol HDL 51 Solid Tumors criteria 51 baseline serum creatinine 51 #.#ng/ml 51 interrater reliability 51 Health Assessment Questionnaire 51 Noncritical violations found 51 lowest tertile 51 ng ml 51 SCr 51 diabetes NIDDM 51 serum insulin 51 systolic blood pressures 51 vitamin D intakes 51 deciliter 51 serum glucose 51 tolterodine ER 50 aminotransferase levels 50 Oral Glucose Tolerance 50 ° C. Brush 50 hypercholesterolaemia 50 GOVERNMENT MEETINGS 50 posttreatment 50 inotropic 50 mCi kg 50 NIHSS score 50 irbesartan 50 confidence interval #.#-#.# 50 oxycodone CR 50 mcg BID 50 pbb 50 neuropathy sensory 50 NCT# ClinicalTrials.gov 50 antihypertensive medications 50 Ejection Fraction 50 dexamethasone Decadron 50 ETDRS 50 arterial thromboembolic events 50 serum CRP 50 Homocysteine levels 50 paraprotein 50 UPDRS 50 mg ustekinumab 50 micromolar 50 FEV1 50 ppm deg 50 plasma glucose concentrations 50 HDL LDL 50 #mg dose [003] 50 #mg #mg #mg [003] 50 #ng/ml 50 leucopenia 50 suppl #S #S 50 ppm boron 50 parous women 50 hemoglobin concentration 50 COPD exacerbation 50 fasting glucose levels 50 Hazard Ratio = 50 rimonabant #mg 50 hypertensives 50 1ppm 50 Triglyceride 50 nonfasting 50 ATV RTV 50 http:/events.fai.org 50 cells mcL 50 carbohydrate oxidation 50 International Prostate Symptom 50 exhaled nitric oxide 50 5-FU/LV 50 Bob Eberline 50 blood oxygen saturation 50 infliximab monotherapy 50 mcg QD 50 Kaplan Meier estimates 50 lactulose 50 fasting serum 50 serum leptin 50 ng mL 50 receiving prophylactic anticoagulation 50 HbA 1C 50 aminotransferase elevations greater 50 CHD mortality 50 bone density glucose 50 CK MB 50 cardiac perfusion 50 tHcy 50 μg 50 receiving PEGINTRON 50 colorectal adenoma 50 MULTAQ 50 creatine kinase MB 50 ADCS ADL 50 deoxy 50 elevated triglyceride levels 50 intravenous bolus 50 mg hydrochlorothiazide 50 mg kg hr 50 seroprotection 50 J Am Podiatr 50 BENICAR 50 FOLFIRI alone 50 diuretic chlorthalidone 50 concomitant medications 50 sulfonylurea metformin 50 glomerular filtration 50 mcg Albuferon 50 prehypertensive 50 #mg QD [002] 50 oral antidiabetic medications 50 % CI #.#-#.# [007] 50 intraobserver 50 systemic embolism 50 mg Lucentis 50 D dimer 50 g cm 50 A1c 50 rFSH 50 del 5q MDS 50 metformin sulfonylurea 50 mmol L 50 mg d 50 Homes Sold tbr 50 Calcium intake 50 6MWD 50 rizatriptan 50 Expanded Disability Status 50 Ultane Sevorane 50 ejection fractions 50 serum phosphorous 50 RBC transfusion 50 nicardipine 50 homocysteine concentrations 50 Bq/m3 50 ± SEM 50 transaminase levels 50 = .# 50 mg q#h 50 INVEGA ® 50 nonobese 50 simvastatin #mg 50 DETROL LA 50 ACTEMRA TM 50 achieved statistical significance 50 elevated uric acid 50 micromoles 50 protein excretion 50 kΩ 50 generalized edema 50 creatine kinase 50 mmHg 50 Flu Cy 50 tolvaptan 50 ^ F FDG 50 density lipoprotein cholesterol 50 pmol 50 cardio respiratory fitness 50 ¾ î 50 kBq 50 atherothrombotic events 50 aldosterone antagonists 50 placebo dexamethasone 50 linoleic acid LA 50 ± 50 laboratory abnormalities 50 fasting lipid 50 hemoglobin hematocrit 50 tapentadol ER 50 neutrophil count 50 IBDQ 50 inhaled fluticasone 50 Interrater reliability 50 Alzheimer Disease Assessment 50 symptom severity 50 micrograms mL 50 diastolic blood pressures 50 nanograms milliliter 50 microfarads 50 balsalazide 50 lactate dehydrogenase LDH 50 nonpregnant women 50 liver histology 50 dosing cohorts 50 Lucentis monotherapy 50 neurologic progression 50 μH 50 p = #.# [003] 50 Peg IFN 50 osmolality 50 Left Ventricular Ejection Fraction 50 serum albumin 50 CHANGE WEEKLY CHANGE 50 John Klimacek 50 inadequate glycemic 50 peginterferon alfa 2a 50 mu g 50 cTnI 50 liver transaminases 50 adjunctive ABILIFY 49 oral antidiabetic drugs 49 log# reduction 49 leukopenia 49 BMI z 49 Cystatin C 49 carotid intima media 49 methacholine challenge 49 fructose diet 49 GH deficiency 49 gm dl 49 log# IU mL 49 bronchial reactivity 49 triglycerides TG 49 plasma glucose concentration 49 #mg doses [002] 49 CANCIDAS 49 FEV ^ sub 49 urinary BPA 49 NYHA class 49 systolic BP 49 OS = ISD/#/#/# 49 dose dabigatran 49 HER2 expression 49 presumes intoxication 49 nonsignificant difference 49 undetectable HCV RNA 49 HF ACTION 49 EDSS scores 49 B overcollateralization OC 49 √ Hz 49 dose titration 49 nM 49 Pearson correlation coefficient 49 secondary efficacy endpoint 49 Skin sterol 49 lymphocyte count 49 steroid dexamethasone 49 hs CRP 49 GBX#.# [002] 49 Cmax 49 HDL cholesterol triglycerides 49 alkaline phosphatase 49 ug dl 49 BUPHENYL R sodium phenylbutyrate 49 peptide BNP 49 angiographic restenosis 49 preoperative PSA 49 ALT elevations 49 FOLFOX4 49 sputum eosinophils 49 #mV V 49 repaglinide 49 lipoprotein levels 49 NUMBER OF TRADERS 49 CDAI 49 microalbuminuria 49 hepatic glucose production 49 cTnT levels 49 antibody titer 49 polyp recurrence 49 adiponectin concentrations 49 definite stent thrombosis 49 Islands Sportfishing 49 gastric pH 49 multivariable analysis 49 Severe hypoglycemia 49 STILL LOW 49 albumin creatinine ratio 49 pulmonary capillary wedge 49 attain statistical significance 49 #/#mmHg 49 endometrial thickness 49 serum TSH 49 cEVR 49 postprocedure 49 Fasting glucose levels 49 inhibin 49 elevated transaminases 49 bilirubin liver 49 ATACAND 49 complete cytogenetic response 49 HDL cholesterol HDL 49 BPH Symptom Score 49 mcg ml 49 dapagliflozin plus 49 proteinuria 49 DULERA 49 RNA copies mL 49 cytogenetic response 49 carotid IMT 49 mg kg bw 49 #mm Hg 49 BMS p = 49 hyperphosphatemia elevated serum phosphorous 49 transaminase elevations 49 abdominal circumference 49 oral levofloxacin 49 partial remissions 49 oxygen desaturation 49 mg kg Hematide 49 Non inferiority 49 #.#Ω 49 racemic albuterol 49 aminotransferase ALT 49 LS BMD 49 octreotide LAR 49 ug dL 49 Â ± 49 pharmacokinetic PK profile 49 deep venous thromboses 49 GnRH agonist 49 μF 49 Nephrol 49 Hgb 49 fullyear outturn represents 49 + #.#mm 49 hypocalcemia 49 gr t Au 49 rapid virological response 49 plus methotrexate 49 nH 49 advanced adenoma 49 placebo p = 49 lopinavir r 49 LEXIVA r 49 TC HDL 49 serum phosphate levels 49 glucose tolerance test 49 oral allopurinol 49 mol L 49 CI -#.# -#.# 49 megohms 49 pCi 49 serum thyroglobulin 49 g dL 49 C Reactive Protein 49 nonpregnant adults 49 subscore 49 PUFA intake 49 plasma homocysteine 49 NATRECOR ® 49 collateralization OC 49 hypogonadal 49 Endothelial function 49 plasma glucose 49 TRUEresult 49 meters grading #.#g [002] 49 len = 49 MILLION SHARES 49 AVANDIA 49 bolus dose 49 pravastatin therapy 49 Sustained virologic response 49 procalcitonin 49 r2 = 49 salivary cortisol 49 nitroprusside 49 FEV1 forced expiratory 49 uL 49 Hematocrit 49 HDL C 49 apolipoprotein A1 49 cm -3 49 MMSE scores 49 XIENCE V vs. 49 A1C 49 Myoglobin 49 titrated glipizide 49 stent binary restenosis 49 receiving ISENTRESS 49 budesonide formoterol 49 systolic hypertension 49 thyroglobulin 49 echocardiographic parameters 49 triacylglycerols 49 n Cooling Degree 49 alanine transaminase ALT 49 urinary protein 49 Si#DB 49 metformin sulfonylureas 49 total cholesterol HDL 49 mg p = 49 placebo PBO 49 cholesterol triglyceride 49 tirofiban 49 apnea hypopnea index 49 creatine phosphokinase 49 APTIVUS r 49 mso header 49 abnormal lipid levels 48 β blocker 48 P ≤ 48 viral titers 48 subtherapeutic 48 CIN3 48 salivary flow 48 HCTZ